Foscarnet
As of the edition of 20 October 2026, Foscarnet is a small molecule: marketed, first approved in 1991 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Foscavir
- First approved
- 27 September 1991 (US)
- Approvals on record
- 6 in 3 regions
- Holder of the most recent approval
- Clinigen; 3 holders in all
- Registered trials
- 28, 2 stopped early
- Disease areas
- Infections; Immune system; Urinary and reproductive; Eye; Nutrition and metabolism; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 5 | 1 | 0 |
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 5 | 3 | 0 | 1 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 5 | 5 | 0 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astra | Originator and Lead sponsor of trials | 1991 to now |
| Clinigen Healthcare | Acquired holder | 2011 to now |
| Clinigen | Applicant | 2019 to now |
| AstraZeneca | Later holder |